Resolution ctDx Lung^™

The Resolution ctDx Lung^TM assay includes actionable genes for targeted FDA-approved therapies or therapies in clinical trials.

Benefits

• An assay that only focuses on genes implicated in lung cancer
• Liquid biopsies can offer a complete picture of tumor heterogeneity
• Useful when tissue biopsies are limited or unobtainable from the patient
• Non-invasive method with testing performed on a blood sample
• Faster turn-around time compared to tissue NGS profiling¹

Clinical Response Data

In a prospective clinical study, the Resolution ctDx Lung assay demonstrated the following performance¹:

• Somatic mutations detected in 64% (135/210) of patients

• 97% (34/35) of patients who received plasma-directed therapy had a clinical and radiological response to the matched targeted therapy

• 46% (96/210) of patients had an oncogenic driver alteration detected, including actionable mutations in EGFR, ALK, MET, BRAF, ROS1, and RET

• 90% (60/67) positive concordance between plasma and tissue NGS testing. Sub-analysis demonstrated

• 96% (49/51) positive concordance within NCCN® oncogenic recognized driver alterations in lung cancer.

Gene List

The Resolution ctDx Lung™ assay targets actionable, somatic SNVs, indels,
fusions, and copy number variants in 22 genes in NSCLC.²